A chimeric dengue virus vaccine candidate delivered by high density microarray patches protects against infection in mice.

Choo, Jovin J Y; Vet, Laura J; McMillan, Christopher L D; Harrison, Jessica J; Scott, Connor A P; Depelsenaire, Alexandra C I; Fernando, Germain J P; Watterson, Daniel; Hall, Roy A; Young, Paul R; Hobson-Peters, Jody; Muller, David A

Choo, Jovin J Y; Vet, Laura J; McMillan, Christopher L D; Harrison, Jessica J; Scott, Connor A P; Depelsenaire, Alexandra C I; Fernando, Germain J P; Watterson, Daniel; Hall, Roy A; Young, Paul R; Hobson-Peters, Jody; Muller, David A.

Afiliação

Choo JJY; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
Vet LJ; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
McMillan CLD; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
Harrison JJ; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
Scott CAP; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
Depelsenaire ACI; Vaxxas Pty Ltd, Translational Research Institute, Brisbane, QLD, Australia.
Fernando GJP; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
Watterson D; Vaxxas Pty Ltd, Translational Research Institute, Brisbane, QLD, Australia.
Hall RA; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
Young PR; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
Hobson-Peters J; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
Muller DA; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia. j.peters2@uq.edu.au.

NPJ Vaccines ; 6(1): 66, 2021 May 07.

Article em En | MEDLINE | ID: mdl-33963191

RESUMO

Dengue viruses (DENV) cause an estimated 390 million infections globally. With no dengue-specific therapeutic treatment currently available, vaccination is the most promising strategy for its control. A wide range of DENV vaccines are in development, with one having already been licensed, albeit with limited distribution. We investigated the immunogenicity and protective efficacy of a chimeric virus vaccine candidate based on the insect-specific flavivirus, Binjari virus (BinJV), displaying the structural prM/E proteins of DENV (BinJ/DENV2-prME). In this study, we immunized AG129 mice with BinJ/DENV2-prME via a needle-free, high-density microarray patch (HD-MAP) delivery system. Immunization with a single, 1 µg dose of BinJ/DENV2-prME delivered via the HD-MAPs resulted in enhanced kinetics of neutralizing antibody induction when compared to needle delivery and complete protection against mortality upon virus challenge in the AG129 DENV mouse model.

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: NPJ Vaccines Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália